Vascular Interventional Advances (VIVA)

The VIVA Foundation is a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education, research, advocacy, and collaboration. It hosts the VIVA (Vascular InterVentional Advances) and The VEINS (Venous Endovascular INterventional Strategies) annual conferences. The VIVA Foundation also presents the Vascular Leaders Forum and collaborates with other industry-leading groups to move the field forward.

Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Late-breaking data from the LIFE-BTK clinical trial showed that the Esprit BTK bioresorbable scaffold system offered better two-year outcomes than balloon angioplasty in severe peripheral artery disease (PAD) below the knee.
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Multiple late-breaking presentations at VIVA 2024 in Las Vegas focused on the benefits of treating peripheral artery disease with the company's intravascular lithotripsy portfolio.
Drug-coated balloons an effective tool in the battle against femoropopliteal disease
Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes.
Late-breaking study examines IVL’s safety and effectiveness among real-life PAD patients
The new study, based on data from nearly 1,400 PAD patients who were treated with Shockwave Medical's IVL technology, was presented at VIVA22 in Las Vegas.
Many PAD patients are missing out on vital risk assessments
The findings, based on Medicare data, were presented at VIVA21 in Las Vegas.

Quality of life improves dramatically following stenting in patients with peripheral artery disease

Data from a study led by researchers at Saint Luke's Mid America Heart Institute<http://globalmessaging1.prnewswire.com/clickthrough/servlet/clickthrough?msg_id=7563978&adr_order=59&url=aHR0cDovL3d3dy5zYWludGx1a2VzaGVhbHRoc3lzdGVtLm9yZy9zZXJ2aWNlcy9oZWFydC1hbmQt%0AdmFzY3VsYXItY2FyZGlvdmFzY3VsYXItc2VydmljZXM%3D> showed marked, long-term improvement in health status in patients suffering from peripheral artery disease treated with the S.M.A.R.T. Nitinol Self-Expandable Stent. The study was sponsored by Cordis Corporation, (Fremont, Calif.), manufacturer of the S.M.A.R.T. Stent.

October 9, 2013

ED as a Vascular Disease: Stents & Interventions

Stenting stenosis in the internal pudendal artery as a treatment for erectile dysfunction (ED) appears to be safe and effective, but more needs to be understood about disease prevalence and pelvic vasculature, cardiologists say. More immediate is leveraging ED to reduce cardiovascular risk factors.

December 19, 2011

Around the web

Health Imaging

Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Vascular Interventional Advances (VIVA)

Bioresorbable BTK stent superior to ballon angioplasty at 2 years

Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients

Drug-coated balloons an effective tool in the battle against femoropopliteal disease

Late-breaking study examines IVL’s safety and effectiveness among real-life PAD patients

Many PAD patients are missing out on vital risk assessments

Around the web